Current pharmacological approaches for prevention and treatment of AML relapse include the use of FMS-like tyrosine kinase 3 (FLT3) kinase inhibitors (5, 11, 12), immune checkpoint inhibitors (ICIs) (13–17), HMA (8, 18), B cell lymphoma 2 (BCL-2) inhibitors (19), mouse double minute 2 (MDM2) inhibition (20), and others (21). Here, FLT3 is linked to acute myeloid leukemia.